Form 4: Madrigal Pharmaceuticals Director Richard S. Levy Executes Stock Options and Sells Shares Under 10b5-1 Plan

Director Richard S. Levy exercised stock options and sold shares of Madrigal Pharmaceuticals under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On April 1, 2024, Richard S. Levy, a director of Madrigal Pharmaceuticals, exercised stock options to acquire 11,000 shares of common stock.
• These options were exercised at prices of $7.36 and $111.06 per share.
• On the same day, Levy sold 11,000 shares of common stock in a series of transactions at prices ranging from $255.899 to $267.0733.
• These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 30, 2023.
• Following these transactions, Levy directly owns 10,298 shares of Madrigal Pharmaceuticals common stock.
• Levy also holds options to purchase 15,000 shares of common stock at $7.36 and no shares at $111.06.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports insider trading activity under a pre-arranged plan, which is a common and legal practice.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like directors and officers, trade their company's stock. These filings provide transparency into insider transactions and are closely watched by investors.

Comparison to Industry Standards

• Insider transactions are a normal part of corporate governance.
• The use of a 10b5-1 trading plan is a common practice to allow insiders to sell shares without being accused of trading on non-public information.
• Comparable companies such as Viking Therapeutics and Intercept Pharmaceuticals also have similar insider trading activities that are publicly disclosed through Form 4 filings.

Stakeholder Impact

• The transactions may have a minor impact on shareholders as they reflect insider selling activity.
• However, the existence of a 10b5-1 plan suggests that these sales are pre-planned and not necessarily indicative of the director's view on the company's future prospects.

Key Dates